Sign in to fuzzto save your conversations, follow your research and come back anytime.
Hikal
HIKAL
NSE
BSE
NSEBSESectorHealthcare
240.36
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Hikal shows strong operational recovery in FY26, but Q1 FY27 earnings cool as revenues normalize and a one-off charge impacts profits.
Depreciation rises from ₹39 Cr in Q1 FY26 to ₹43 Cr in Q1 FY27, reflecting consistent asset base expansion.
Consolidated EBITDA falls from ₹105 Cr in Q4 FY26 to ₹37 Cr in Q1 FY27, highlighting seasonal earnings volatility.
Expenditure eases from ₹414 Cr in Q4 FY26 to ₹366 Cr in Q1 FY27, showing active cost control.
EBITDA margin cools from 20.3% in Q4 FY26 to 9.2% in Q1 FY27, indicating margin normalization after a strong peak.
Interest costs decline from ₹17 Cr in Q1 FY26 to ₹15 Cr in Q1 FY27, indicating steady debt servicing.
Net profit reverses from a ₹40 Cr gain in Q4 FY26 to a ₹7 Cr loss in Q1 FY27, driven by lower volumes and a one-off charge.
Pharmaceuticals EBIT recovers from a loss of ₹26 Cr in Q1 FY26 to a profit of ₹8 Cr in Q1 FY27, confirming an operational turnaround.
Core PBT drops from ₹55 Cr in Q4 FY26 to a loss of ₹19 Cr in Q1 FY27, signaling underlying profitability pressure.
